Cells for producing recombinant iduronate-2-sulfatase

The present invention provides methods and compositions for production of recombinant iduronate-2-sulfatase (I2S). The invention encompasses the discovery that more potent recombinant I2S protein can be produced by cells engineered to co-express a recombinant I2S protein and a formylglycine generati...

Full description

Saved in:
Bibliographic Details
Main Authors Boldog, Ferenc, Heartlein, Michael
Format Patent
LanguageEnglish
Published 20.12.2019
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention provides methods and compositions for production of recombinant iduronate-2-sulfatase (I2S). The invention encompasses the discovery that more potent recombinant I2S protein can be produced by cells engineered to co-express a recombinant I2S protein and a formylglycine generating enzyme (FGE). According to the invention, a cell in cell culture conditions produces I2S protein comprising at least about 70% conversion of the cysteine residue corresponding to Cys59 to Cα-formylglycine (FGly), and at a specific productivity rate of greater than about 30 picogram/cell/day and/or at a level of I2S between 0.3-fold and 10-fold higher than the level of formylglycine generating enzyme. Such cells are adaptable to various cell culture conditions, and in some embodiments are adaptable to a large-scale suspension serum-free culture. Recombinant I2S produced in accordance with the present invention can be used in enzyme replacement therapy, for example in treating Hunter syndrome.
Bibliography:Application Number: NZ20130734670